Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

17 Nov 2017
Change (% chg)

$-0.05 (-0.47%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Alder Biopharmaceuticals Q3 loss per share $0.92
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals announces third quarter 2017 financial and operating results.Q3 loss per share $0.92.Q3 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.Alder Biopharmaceuticals Inc - ‍eptinezumab biologics license application (BLA) submission on track for 2h18​.Alder Biopharmaceuticals Inc - ‍promise 2 pivotal trial completed enrollment and top-line data on track for 1h18​.Alder-Sees available cash & cash equivalents, short-term investments to be sufficient for projected requirements through late 2018/early 2019​‍​.  Full Article

Alder Biopharmaceuticals posts Q2 loss $0.79/shr
Wednesday, 27 Jul 2016 

Alder Biopharmaceuticals Inc : Alder Biopharmaceuticals reports second quarter 2016 financial and operating results . Q2 shr loss $0.79 . Q2 shr view $-0.75 -- Thomson Reuters I/B/E/S . Alder did not record any revenue in Q2 of 2015 . Net loss for Q2 ended June 30, 2016, totaled $38.9 mln, or $0.79 per share .Q2 shr view $-0.75 -- Thomson Reuters I/B/E/S.  Full Article

Alder Biopharmaceuticals licenses clazakizumab rights to Vitaeris
Friday, 6 May 2016 

Alder Biopharmaceuticals Inc : Alder biopharmaceuticals licenses clazakizumab rights to vitaeris . Says in exchange for rights to clazakizumab, alder has received an equity stake in vitaeris . In addition, randall c. Schatzman, president and ceo of alder, has joined vitaeris' board of directors .Specific financial and other terms of transaction were not disclosed.  Full Article

Alder BioPharmaceuticals Inc announces commencement of public offering of common stock
Thursday, 7 Apr 2016 

Alder BioPharmaceuticals Inc:Intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.  Full Article

BRIEF-Alder Biopharmaceuticals Q3 loss per share $0.92

* Alder biopharmaceuticals announces third quarter 2017 financial and operating results